Report : North America Breast Cancer Screening Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Test Type (Blood Marker tests, Imaging Test, Genetic Test, Immunohistochemistry Test); End User (Hospitals, Diagnostic Centers, Cancer Institutes, Research Laboratories), and Countries
Imaging Test Segment to Dominate North America Breast Cancer Screening Market during 2020–2027
According to The Insight Partners market research study on “North America Breast cancer screening Market to 2027 – Regional Analysis and Forecast by Test Type and End User,” is expected to reach US$ 2,832.04 Mn by 2027 from US$ 2,064.26 Mn in 2019. The market is estimated to grow at a CAGR of 5.1% from 2020 to 2027.The report provides trends prevailing in the North America breast cancer screening market along with the rivers and restraints pertaining to the market growth. The growth of the North American breast cancer screening market is attributed to the growing prevalence of breast cancer and increasing number of initiatives and investments pertaining to breast cancer management. However, the high cost associated with breast cancer screening hinders the market growth.
The breast cancer screening market, by test type, is segmented into blood marker tests, imaging test, genetic test, and Immunohistochemistry test. The imaging test segment held the largest share of the North American market in 2019; moreover, it is anticipated to register the highest CAGR of 5.1% in the market during the forecast period. The imaging tests explain the view of areas located inside the body, and advancements in the imaging technology for screening of breast cancer is fueling the adoption of imaging tests in the breast cancer screening.
Koninklijke Philips N.V., Hologic, Inc., Becton, Dickinson and Company, Myriad Genetics, Inc., Siemens Healthcare AG, Exact Sciences Corporation, OncoCyte Corporation, POC Medical systems, Danaher Corporation, and General Electric Company are among the leading companies in the breast cancer screening market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in January 2018, GE Healthcare launched Serena Bright that is claimed to be the healthcare sector’s first contrast-enhanced mammography solution for biopsy.
The report segments the North America breast cancer screening market as follows:
Breast Cancer Screening Market – By Test Type
Breast Cancer Screening Market – By End User
Breast Cancer Screening Market – By Country